A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

BACKGROUND: For unresectable stage III non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC harboring driver-gene mutations benefit from Tyrosine Kinase Inhibitors (TKIs) Therapy. In a real-world setting, there is room for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ranpu, Yu, Shaorong, Ye, Jinjun, Wang, Yimin, Zhao, Zhiting, Liu, Hongbing, Song, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311792/
https://www.ncbi.nlm.nih.gov/pubmed/34322390
http://dx.doi.org/10.3389/fonc.2021.692703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311792/
https://www.ncbi.nlm.nih.gov/pubmed/34322390
http://dx.doi.org/10.3389/fonc.2021.692703

Ejemplares similares